Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.

Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration

Open access
Verma, Manish, Lizama, Britney N., Chu, Charleen T. · 2022 · Translational Neurodegeneration

Abstract

Glutamate is the most commonly engaged neurotransmitter in the mammalian central nervous system, acting to mediate excitatory neurotransmission. However, high levels of glutamatergic input elicit excitotoxicity, contributing to neuronal cell death following acute brain injuries such as stroke and trauma. While excitotoxic cell death has also been implicated in some neurodegenerative disease models, the role of acute apoptotic cell death remains controversial in the setting of chronic neurodegeneration. Nevertheless, it is clear that excitatory synaptic dysregulation contributes to neurodegeneration, as evidenced by protective effects of partial N -methyl- D -aspartate receptor antagonists. Here, we review evidence for sublethal excitatory injuries in relation to neurodegeneration associated with Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis and Huntington’s disease. In contrast to classic excitotoxicity, emerging evidence implicates dysregulation of mitochondrial calcium handling in excitatory post-synaptic neurodegeneration. We discuss mechanisms that regulate mitochondrial calcium uptake and release, the impact of LRRK2, PINK1, Parkin, beta-amyloid and glucocerebrosidase on mitochondrial calcium transporters, and the role of autophagic mitochondrial loss in axodendritic shrinkage. Finally, we discuss strategies for normalizing the flux of calcium into and out of the mitochondrial matrix, thereby preventing mitochondrial calcium toxicity and excitotoxic dendritic loss. While the mechanisms that underlie increased uptake or decreased release of mitochondrial calcium vary in different model systems, a common set of strategies to normalize mitochondrial calcium flux can prevent excitatory mitochondrial toxicity and may be neuroprotective in multiple disease contexts.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40035-021-00278-7

Cites

179 of 179 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 A combination of factors conspire to promote excitatory mitochondrial toxicity (EMT). (1) Pathophysiological processes linked to neuronal hyperexcitability have been identified in several neurodegenerative disorders. Chronic elevations in cytosolic calcium flux due to neuronal hyperexcitability elicit increased demand for mitochondrial calcium buffering. When hyperexcitability is combined with altered mitochondrial calcium handling and/or other factors that enhance susceptibility to mitochondrial injury, EMT may occur. (2) A set of intrinsic changes in mitochondrial calcium handling are triggered by familial neurodegeneration gene mutations that elicit increased mitochondrial calcium uptake and/or decreased mitochondrial calcium release. Mutations in LRRK2 and SOD1 increase MCU expression, while PINK1 loss-of-function results in decreased phosphorylation and activities of NCLX and LETM1. NCLX is also decreasd in sporadic AD brains and tau inhibits NCLX activity. In some contexts, MCU expression is decreased rather than increased. This has been proposed as a compensatory response, but may still contribute to EMT by exacerbating cytosolic calcium elevations. Alternatively, MCU may be regulated differently in neurons than in glia. (3) Post-synaptic mitochondria are most vulnerable to EMT, and injured mitochondria are removed from dendrites by mitophagy. Elevated mitophagy that is not balanced by mitochondrial replacement results in mitochondrial depletion from dendrites. LOF mutations in the genes encoding PINK1 and Parkin impair mitochondrial biogenesis, while PINK1 mutations and hyperphosphorylation of tau contribute to impaired mitochondrial transport. The resulting loss of mitochondrial support leads to dendritic atrophy, an early sign of neurodegeneration. (4) Many neurodegenerative disease-associated genes also elicit altered calcium handling in other organelles. These alterations, particularly those at the ER-mitochondrial contact sites, may also contribute to dysregulation of cytosolic and/or mitochondrial calcium, although the exact relationships have not been directly addressed. Neurodegenerative disease-linked proteins (genes) include amyloid precursor protein (APP), glucocerebrosidase (GBA), huntingtin (HTT), leucine-rich repeat kinase 2 (LRRK2), Tau (MAPT), PTEN-induced kinase 1 (PINK), presenilin 1 and 2 (PSEN1/2), alpha-synuclein (SNCA) and superoxide dismutase 1 (SOD1). Mut, mutation; LOF, loss-of-function
Fig. 1 A combination of factors conspire to promote excitatory mitochondrial toxicity (EMT). (1) Pathophysiological processes linked to neuronal hyperexcitability have been identified in several neurodegenerative disorders. Chronic elevations in cytosolic calcium flux due to neuronal hyperexcitability elicit increased demand for mitochondrial calcium buffering. When hyperexcitability is combined with altered mitochondrial calcium handling and/or other factors that enhance susceptibility to mitochondrial injury, EMT may occur. (2) A set of intrinsic changes in mitochondrial calcium handling are triggered by familial neurodegeneration gene mutations that elicit increased mitochondrial calcium uptake and/or decreased mitochondrial calcium release. Mutations in LRRK2 and SOD1 increase MCU expression, while PINK1 loss-of-function results in decreased phosphorylation and activities of NCLX and LETM1. NCLX is also decreasd in sporadic AD brains and tau inhibits NCLX activity. In some contexts, MCU expression is decreased rather than increased. This has been proposed as a compensatory response, but may still contribute to EMT by exacerbating cytosolic calcium elevations. Alternatively, MCU may be regulated differently in neurons than in glia. (3) Post-synaptic mitochondria are most vulnerable to EMT, and injured mitochondria are removed from dendrites by mitophagy. Elevated mitophagy that is not balanced by mitochondrial replacement results in mitochondrial depletion from dendrites. LOF mutations in the genes encoding PINK1 and Parkin impair mitochondrial biogenesis, while PINK1 mutations and hyperphosphorylation of tau contribute to impaired mitochondrial transport. The resulting loss of mitochondrial support leads to dendritic atrophy, an early sign of neurodegeneration. (4) Many neurodegenerative disease-associated genes also elicit altered calcium handling in other organelles. These alterations, particularly those at the ER-mitochondrial contact sites, may also contribute to dysregulation of cytosolic and/or mitochondrial calcium, although the exact relationships have not been directly addressed. Neurodegenerative disease-linked proteins (genes) include amyloid precursor protein (APP), glucocerebrosidase (GBA), huntingtin (HTT), leucine-rich repeat kinase 2 (LRRK2), Tau (MAPT), PTEN-induced kinase 1 (PINK), presenilin 1 and 2 (PSEN1/2), alpha-synuclein (SNCA) and superoxide dismutase 1 (SOD1). Mut, mutation; LOF, loss-of-functionCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 179 references

Research works printed but not linked: 1

  1. Hockey LN, Kilpatrick BS, Eden ER, Lin-Moshier Y, Brailoiu GC, Brailoiu E, et al. Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition. J Cell Sci. 2015;128(2):232–8.

Cited by

See all 451

Metadata

Authors
Verma, M., Lizama, B. N., & Chu, C. T.
Affiliations
University of Pittsburgh (US)
Corresponding author
Chu, Charleen T.
Venue
Translational Neurodegeneration
Published
2022-01-25
Volume
11
Issue
1
Pages
3-3
ISSN
2047-9158 (ISSN-L)
OpenAlex
W4213195620
Cited by
451
References
179
Citations by year
2026: 92 · 2025: 146 · 2024: 118 · 2023: 75 · 2022: 20
FWCI
9.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Translational Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Foundation for the National Institutes of Health (AG026389, NS065789, NS101628)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
excitotoxicity, glutamate, mitochondrial calcium handling, NMDA receptor antagonists, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, LRRK2, PINK1, Parkin, amyloid-beta, glucocerebrosidase, autophagy, neuroprotection
MeSH terms
Animals, Mammals, Mitochondria, Neurons, Parkinson Disease, Glutamic Acid, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration. https://app.cochat.ai/papers/10.1186/s40035-021-00278-7
The paper
Verma, M., Lizama, B. N., & Chu, C. T. (2022). Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration. Translational Neurodegeneration. https://doi.org/10.1186/s40035-021-00278-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.